
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - While the risk of malignant conversion of nevus sebaceous has been a subject of recent controversy, pediatric dermatologist Sheila Fallon Friedlander, M.D., still recommends prophylactic surgical excision of such lesions prior to adolescence.